Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine

被引:11
作者
Tang, Hsin-Chieh [1 ]
Chen, Calvin Yu-Chian [1 ,2 ,3 ,4 ]
机构
[1] Asia Univ, Dept Biomed Informat, Taichung 41354, Taiwan
[2] China Med Univ, Dept Med, Taichung 40402, Taiwan
[3] China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan
[4] China Med Univ Hosp, Dept Med Res, Human Genet Ctr, Taichung 40447, Taiwan
关键词
CELL-CYCLE; PROTEIN; CANCER; RESISTANCE; EXPRESSION; POTENT; CDK2; GENE; P21; SIMULATION;
D O I
10.1155/2014/798742
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
One has found an important cell cycle controller. This guard can decide the cell cycle toward proliferation or quiescence. Cyclin-dependent kinase 2 (CDK2) is a unique target among the CDK family in melanoma therapy. We attempted to find out TCM compounds from TCM Database@Taiwan that have the ability to inhibit the activity of CDK2 by systems biology. We selected Tetrahydropalmatine, Reserpiline, and (+)-Corydaline as the candidates by docking and screening results for further survey. We utilized support vectormachine (SVM), multiple linear regression (MLR) models and Bayesian network for validation of predicted activity. By overall analysis of docking results, predicted activity, and molecular dynamics (MD) simulation, we could conclude that Tetrahydropalmatine, Reserpiline, and (+)-Corydaline had better binding affinity than the control. All of them had the ability to inhibit the activity of CDK2 and might have the opportunity to be applied in melanoma therapy.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
    Yang, Liu
    Fang, Dongdong
    Chen, Huijun
    Lu, Yiyu
    Dong, Zheng
    Ding, Han-Fei
    Jing, Qing
    Su, Shi-Bing
    Huang, Shuang
    ONCOTARGET, 2015, 6 (25) : 20801 - 20812
  • [32] Coupling function of cyclin-dependent kinase 2 and Septin2 in the promotion of hepatocellular carcinoma
    Xu, Chenzhou
    Zhang, Wei
    Zhang, Xuening
    Zhou, Danhua
    Qu, Lishuai
    Liu, Jinxia
    Xiao, Mingbing
    Ni, Runzhou
    Jiang, Feng
    Ni, Wenkai
    Lu, Cuihua
    CANCER SCIENCE, 2019, 110 (02) : 540 - 549
  • [33] Bombyx mori cyclin-dependent kinase inhibitor is involved in regulation of the silkworm cell cycle
    Tang, X. -F.
    Zhou, X. -L.
    Zhang, Q.
    Chen, P.
    Lu, C.
    Pan, M. -H.
    INSECT MOLECULAR BIOLOGY, 2018, 27 (03) : 404 - 413
  • [34] Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review
    Volkart, Priscylla Andrade
    Bitencourt-Ferreira, Gabriela
    Souto, Andre Arigony
    de Azevedo, Walter Filgueira, Jr.
    CURRENT DRUG TARGETS, 2019, 20 (07) : 716 - 726
  • [35] Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors
    Duca, Jose S.
    FUTURE MEDICINAL CHEMISTRY, 2009, 1 (08) : 1453 - 1466
  • [36] Purification and crystallization of cyclin-dependent kinase inhibitor p21
    Mayrose, DR
    Nichols, MA
    Yue, XO
    Ke, HM
    PROTEIN SCIENCE, 1996, 5 (09) : 1928 - 1930
  • [37] Cellular effects of purvalanol A: A specific inhibitor of cyclin-dependent kinase activities
    Villerbu, N
    Gaben, AM
    Redeuilh, G
    Mester, J
    INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (06) : 761 - 769
  • [38] Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
    Adrian M. Senderowicz
    Investigational New Drugs, 1999, 17 : 313 - 320
  • [39] Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials
    Senderowicz, AM
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (03) : 313 - 320
  • [40] The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase
    Kaiser, A
    Nishi, K
    Gorin, FA
    Walsh, DA
    Bradbury, EM
    Schnier, JB
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 386 (02) : 179 - 187